PURPOSE: An explanation for the differential impact of diabetes on coronary heart disease (CHD) mortality in men and women is that diabetes and cardiovascular disease (CVD) share a common antecedent that differentially affects men and women. In the San Antonio Heart Study we examined the relationship between gender, the metabolic syndrome defined by the National Cholesterol Education Program (NCEPMetS) and diabetes and their ability to predict CHD mortality. METHODS: Over 15.5 years, 4996 men and women 25 to 64 years of age experienced 254 cardiovascular deaths, including 121 from CHD (International Classification of Diseases, Ninth Revision codes 410-414). RESULTS: At baseline, NCEP-MetS occurred more often in men than in women among those with normal glucose levels (12.3% vs. 9.7%, p ! 0.05), but less often in men than in women among those with diabetes (65.7% vs. 74.4%, p ! 0.05). Adjusted for age, ethnic group, and a history of CVD, relative to women with neither diabetes nor NCEP-MetS, women with both had a 14-fold (hazard ratio [HR] Z 14.3 [95% confidence interval: 6.62, 30.7]) increased risk of CHD mortality, whereas men had only a 4-fold (HR Z 4.21 (95% confidence interval: 2.32, 7.65]) increased risk, respectively. CONCLUSION: When diabetes occurred with NCEP-MetS, gender was a strong modifier of the joint effect of diabetes and NCEP-MetS on CHD mortality.
INTRODUCTION
At least 3 meta-analyses have examined whether diabetes reduces the gender differential in coronary heart disease (CHD) mortality (1) (2) (3) . Two of the 3 meta-analyses report that the impact of diabetes on the risk of CHD death is greater in women than in men and that standard cardiovascular risk factors do not fully account for this gender difference (1, 3) , while the third meta-analysis reports that elevated levels of the standard cardiovascular risk factors (i.e., age, hypertension, total cholesterol, and smoking) are responsible for the excess relative risk of CHD mortality in women versus men with diabetes (2) . If cardiovascular risk factor levels account for all or part of the attenuation of the CHD mortality gender differential in individuals with diabetes, then, relative to men, women with diabetes must have higher levels of cardiovascular risk factors. This could be explained if diabetes either had a more adverse effect on cardiovascular risk factors in women than in men or diabetes and CHD shared a common antecedent that differentially affected men and women.
An atherogenic state prior to the onset of clinical diabetes that is consistent with a common etiology underlying diabetes and cardiovascular disease (CVD) is suggested by elevated cardiovascular risk factors in prediabetic individuals (4) (5) (6) (7) (8) , elevated cardiovascular risk prior to a clinical diagnosis of diabetes in the Nurses' Health Study (9) , and increased carotid artery intima-media thickness in prediabetic individuals in our Mexico City study (10) . The metabolic syndrome is a strong predictor of type 2 diabetes, and its component parts are elevated in prediabetic individuals. Therefore, the metabolic syndrome, recognized as a cluster of cardiovascular risk factors that frequently coincides with insulin resistance and hyperglycemia (11, 12) , may be an early manifestation of the common etiology underlying diabetes and CHD.
Recently, we reported that there was evidence from the San Antonio Heart Study (SAHS) that sex modified the ability of the metabolic syndrome to predict cardiovascular mortality. Furthermore, when both the metabolic syndrome and diabetes were used to classify individuals and absence of both disorders was used as the referent category, the Selected Abbreviations and Acronyms ARIC Z Atherosclerosis Risk in Communities CHD Z coronary heart disease CVD Z cardiovascular disease HR Z hazard ratio ICD-9 Z International Classification of Diseases, Ninth Revision IFG Z impaired fasting glucose IGR Z impaired glucose regulation IGT Z impaired glucose tolerance NCEP-MetS Z National Cholesterol Education Program-metabolic syndrome SAHS Z San Antonio Heart Study attenuation of the sex difference in cardiovascular mortality was statistically significant only in individuals with both disorders (13) . However, because waist circumference was measured at baseline on only 57% of participants enrolled in phase two of the SAHS, we did not have sufficient power to examine which components of the metabolic syndrome in combination with diabetes were driving the relationship, or examine whether sex modified the ability of the metabolic syndrome and diabetes to predict CHD mortality. In order to have sufficient statistical power, we impute ''high waist circumference'' as a dichotomous trait in phase one SAHS participants based on weight, height and gender. We use this additional power to examine the impact of gender, the metabolic syndrome as defined by the National Cholesterol Education Program (14, 15) (NCEP-MetS), and diabetes on CHD mortality, as well as to examine which components of the metabolic syndrome in combination with diabetes are driving the relationship.
MATERIALS AND METHODS

The SAHS Design and Population
The SAHS cohort consists of 5158 participants, recruited at baseline in two phases: phase 1 between 1979 and 1982, and phase 2 between 1984 and 1988. Details of the study design have been previously published (16) (17) (18) . The Institutional Review Board of the University of Texas Health Science Center at San Antonio approved the study, and all subjects gave informed consent.
Baseline SAHS Cohort Examination
The baseline SAHS cohort examination was standardized and included interviews, blood pressure measurements, anthropometry, a fasting venipuncture (12-hour overnight), and an oral glucose tolerance test (18, 19) . Ethnic group was defined by a validated algorithm (16) . A history of CVD was defined as having had a self-reported physiciandiagnosed heart attack or stroke.
The metabolic syndrome was defined according to the NCEP ATP III criteria. The waist criterion for phase 1 participants (43%; n Z 2217) was imputed using logistic regression from weight and height within gender subgroups. NCEP-MetS was defined (14) as having at least 3 of the following NCEP metabolic abnormalities: fasting glucose >100 mg/dL or taking medication for diabetes (15) ; abdominal obesity (waist circumference O102 cm in men or O88 cm in women); high blood pressure (HBP, >130/> 85 mm Hg) or taking medication for hypertension; triglycerides >150 mg/dL; or high-density lipoprotein (HDL) cholesterol levels (!40 mg/dL in men, !50 mg/dL in women).
Diabetes was defined as fasting plasma glucose >126 mg/ dL, 2-hour postload glucose >200 mg/dL, and/or selfreported, physician-diagnosed diabetes requiring medication (either oral or insulin) (20) . In nondiabetic individuals, impaired glucose tolerance (IGT) was defined as a 2-hour glucose level of >140 mg/dL (20) ; impaired fasting glucose (IFG) was defined as fasting plasma glucose >100 mg/dL; and impaired glucose regulation (IGR) was defined as having IFG and/or IGT.
Study Population, Follow-Up and Events
Of the 5,158 SAHS participants eligible for inclusion, 162 individuals were excluded because the information required to define NCEP-MetS and/or diabetes was missing (n Z 126), they were lost to follow-up since their baseline examination (n Z 32), or their death certificate was missing (n Z 4). Vital status was determined by annual mailed questionnaires, completed by a participant or their next of kin. In cases of nonresponse, we used telephone interviews, home visits, voting records, driver registration, the National Death Index, and addresses from the San Antonio Retail Merchants' Association. Among the 4,996 participants in this study, 61 people had incomplete vital status ascertainment through January 1, 2000 (ascertainment rate Z 98.8%).
Information on cause of death was abstracted from death certificates (with names and ethnic identifiers suppressed) and sent to a certified nosologist (Medical Coding and Consultation Services, Rolesville, NC) for coding according to the International Classification of Diseases, Ninth Revision (ICD-9). CHD mortality was not limited to the underlying cause of death, but was defined as death with the mention anywhere on the death certificate of ICD-9 codes 410-414 (ischaemic).
Statistical Analyses
Prospective analyses were carried out in which NCEP-MetS and diabetes determined a person's exposure status and CHD mortality was the outcome of interest.
Participants were grouped into one of four categories: individuals with neither NCEP-MetS nor diabetes; individuals with NCEP-MetS only; individuals with diabetes only; and individuals with both disorders. Age-and ethnic group-adjusted means and proportions were determined for participant characteristics stratified by sex and the 4 NCEP-MetS/diabetes categories. Age-and ethnic groupadjusted prevalences of each of the NCEP-MetS criterion were determined as stratified by normal glucose regulation, IGR, and diabetes status.
Poisson regression was used to determine age-and ethnic group-adjusted CHD mortality rates stratified by sex and the 4 NCEP-MetS/diabetes categories. Cox proportional hazard models adjusted for age, ethnic group, and a history of CVD were used to calculate hazard ratios (HRs) for CHD mortality in relation to the 4 NCEP-MetS/diabetes categories stratified by sex. Models with the appropriate interaction terms were used to model interactions between sex and the 4 NCEP-MetS/diabetes categories in relation to CHD mortality. For all analyses the assumption of proportional hazards was evaluated by testing for interaction with a continuous time variable.
For each of the 4 NCEP-MetS criteria other than highfasting glucose, 4 NCEP-MetS criterion/diabetes categories were created, and analyses were completed as stated for the 4 NCEP-MetS/diabetes categories.
RESULTS
Of the 4,996 study participants 3,701 (74.1%) had neither NCEP-MetS nor diabetes, 771 (15.4%) had NCEP-MetS only, 138 (2.8%) had diabetes only, and 386 (7.7%) had both disorders. Across these 4 categories, 57.7%, 51.2%, 50.0%, and 61.1%, respectively, were female.
Fasting glucose, body mass index and low-density lipoprotein cholesterol levels were significantly higher in men than in women for individuals without either disorder, whereas in the other categories, levels were similar in both sexes (Table 1) . Two-hour glucose levels were lower in men than in women in all categories except for individuals with diabetes but without the metabolic syndrome, whereas high-density lipoprotein cholesterol levels were lower in men across all 4 categories. Among individuals who did not have diabetes, fasting insulin levels were higher in men than in women among persons without NCEP-MetS, but similar in men and women among persons with NCEP-Mets; whereas 2-hour insulin levels were lower in men than in women regardless of their NCEP-MetS status. Among individuals with diabetes, the duration of diabetes and reported age at onset were similar in men and in women regardless of their NCEP-MetS status.
NCEP-MetS occurred less often in women than in men among those with normal glucose levels (9.7% vs. 12.3%, p ! 0.05), but more often in women than in men among those with diabetes (74.4% vs. 65.7%, p ! 0.01) ( Table 2) . (3) 139 (3) 0 (À7, 8) 171 (1) 167 (2) 5 (0, 9) 2-Hour glucose (mg/dL) 107 (1) 100 (1) 7 (5, 10) 127 (2) 118 (2) 9 (3, 15) 270 (5) 272 (5) À2 (À16, 13) 306 (3) 293 (4) 13 ( 38 (1) 5 (4, 7) 60 (2) 53 (2) 6 (2, 11) 44 (1) 38 (1) 6 (3, 8) Hypertension (%) 9.1 (0.7) 10.6 (0.8) À1.5 (À3.7, 0.6) 37.5 (1.7) 39.5 (1.7) Unadjusted.
x Limited to participants who had waist circumference measured.
Hunt
The prevalence of NCEP-high waist circumference and NCEP-low HDL cholesterol was higher in women than in men across all 3 categories of glucose regulation; moreover, the largest difference between men and women was in individuals with diabetes. The prevalence of NCEP-high triglycerides and NCEP-high blood pressure was similar in men and women only when diabetes was present, while in individuals with normal and impaired glucose regulation, the prevalence was higher in men. Finally, men with IGR or diabetes were more likely than women to have NCEPhigh fasting glucose, with the gender difference being smaller in individuals with diabetes.
Over an average of 15.5 years (range, 11.2 to 20.2 years), 254 CVD deaths occurred, including 121 from CHD. In individuals with neither diabetes nor NCEP-MetS, the CHD mortality rate was higher in men than in women, whereas in individuals with both disorders the CHD mortality rate was similar in men and in women (Table 3) . Interestingly, the male excess in CHD mortality was somewhat preserved in diabetic individuals without NCEP-MetS.
Relative to women with neither diabetes nor NCEPMetS, women with both disorders had a 14-fold (HR Z 14.3 [95% confidence interval: 6.62, 30.7]) increased risk of CHD mortality, whereas men had only a 4.2-fold increased risk (Table 3) . Results were similar when either the 194 individuals who reported a prior physician-diagnosed heart attack or stroke were excluded from the analysis, or when the individual component parts of NCEP-MetS as well as smoking status and low-density lipoprotein (LDL) cholesterol levels were adjusted for as covariates. When the 194 individuals with a history of cardiovascular disease were excluded from the analysis relative to women with neither diabetes nor NCEP-MetS, women with both disorders had a 18-fold (HR Z 18.1 [95% confidence interval: 8.03, 41.0]) increased risk of CHD mortality, whereas men had only a 6.6-fold increased risk (Table 3) . Similarly, when the additional covariates were adjusted for relative to women with neither diabetes nor NCEP-MetS, women with both disorders had a 10-fold increased risk of CHD mortality, whereas men had only a 2.9-fold increased risk.
Because of the limited number of CHD events and limited statistical power, we used cardiovascular mortality as the outcome to test for interaction among the 4 NCEPMetS/diabetes categories, sex, and ethnic group. Although none of the p values for 3-way interaction were statistically significant, there was the suggestion that the gender difference in the HRs for individuals with both disorders relative to individuals with neither disorder was stronger in Mexican Americans than non-Hispanic whites. In Mexican Americans, women had an 11-fold (HR Z 11.2 [95% confidence interval: 6.01, 21.0]) and men had a 3.7-fold (HR Z 3.66 (95% confidence interval: 2.23, 5.98]) increased risk of cardiovascular mortality comparing individuals with diabetes and NCEP-MetS to those without either disorder, while in non-Hispanic whites. corresponding HRs were 3.22 and 2.76 in women and in men, respectively (Table 4) .
Among individuals with diabetes without a history of CVD (n Z 405), we examined whether either the duration of diabetes or 2-hour glucose levels explained the gender differential in increased risk associated with NCEP-MetS for CHD mortality. The CHD mortality HR associated with NCEP-MetS among diabetic individuals was 7.22 (95% confidence interval: 0.96, 54.5) in women and 0.66 (95% confidence interval: 0.26, 1.65) in men (male vs. female p value Z 0.034) adjusted for age and ethnic group. After additional adjustment for duration of diabetes as well as 2-hour glucose levels HRs were 5.53 (95% confidence interval: 0.73, 41.8) and 0.58 (95% confidence interval: 0.23, 1.44) in women and in men, respectively (male vs. female p value Z 0.046).
For each of the NCEP-defined components of the metabolic syndrome, we examined the rates and HRs for CHD mortality in the absence and presence of diabetes (Table 3) . Comparing individuals with both LDL and high-density lipoprotein cholesterol and diabetes relative to those with neither condition, the HR for CHD mortality in women was statistically significantly higher than in men. For high triglyceride levels, the HRs for CHD mortality were statistically significantly higher for women than for men across all 3 comparisons. Comparing individuals with diabetes with and without high waist circumference to individuals with neither disorder, there was the suggestion that the HR for CHD mortality in women was higher than the HR in men. CHD mortality HRs for high blood pressure were similar for women and men across all 3 comparisons. 
DISCUSSION
Gender was a strong modifier of the joint effect of diabetes and the metabolic syndrome on CHD mortality, and the predictive ability of the metabolic syndrome when coupled with diabetes was stronger in women than in men. Not only is the majority of the SAHS population Mexican American, but the prevalence of NCEP-MetS and diabetes is higher in Mexican Americans than in non-Hispanic whites. When we tested for interaction among the NCEP-MetS/diabetes categories, sex, and ethnic group relative to cardiovascular mortality, none of the p values for the 3-way interaction were statistically significant. However, there was a suggestion that the gender difference in HRs for men and women with both NCEP-MetS and diabetes relative to men and women with neither disorder was stronger in Mexican Americans than in non-Hispanic whites. These results suggest that the reduced gender differential in CHD mortality among diabetic individuals observed in many, but not in all, populations (1-3) is more pronounced in populations such as the Mexican American population in which the metabolic syndrome and diabetes are more likely to co-occur. Among individuals with neither the metabolic syndrome nor diabetes, cardiovascular risk factor levels (including fasting glucose, body mass index, LDL, and HDL cholesterol) indicate a higher cardiovascular mortality risk in men relative to that in women. In contrast, among individuals with the metabolic syndrome regardless of whether or not they have diabetes, cardiovascular risk factor levels, with the exception of HDL cholesterol, indicate a similar or lower cardiovascular morality risk in men relative to women. Similarly, for each component part of the metabolic syndrome that has a higher prevalence in women than in men, the greatest sex difference is among individuals with diabetes. In contrast, for each component part of the metabolic syndrome that has a higher prevalence in men than in women, the smallest sex difference is among individuals with diabetes. As a result, the metabolic syndrome is present less often in women than in men among individuals with normal or impaired glucose regulation, but more often in women than in men among individuals with diabetes. A publication from the Atherosclerosis Risk in Communities (ARIC) study limited to nondiabetic individuals reports that men and women with NCEP-MetS were 1.5 and 2 times more likely, respectively, to develop CHD than were control subjects and that there was a significant MetS-sex interaction (21) . Hence, in contrast to our findings they report a significant MetS-sex interaction in individuals without diabetes (21) . The ARIC finding may be explained by a) a failure to exclude all individuals with diabetes because an oral glucose tolerance test was not available, b) the inclusion of nonfatal cardiovascular events, or c) the increased statistical power available in ARIC versus the SAHS.
The current paper not only expands our earlier findings that gender modified the joint effect of diabetes and NCEP-MetS on cardiovascular mortality to include CHD mortality, but also examines the contribution of each component part of the metabolic syndrome. None of the component parts of the metabolic syndrome clearly drove the observed relationship between gender, diabetes, and CHD mortality. While HDL cholesterol and triglyceride levels appear to be of particular interest, it is pertinent to bear in mind that temporal relationships between the component parts of the metabolic syndrome may be important. For instance, because diabetes often causes weight loss, a diabetic individual's current weight and waist circumference may not accurately reflect their prediabetic weight and waist circumference. In addition, despite our attempts to increase the available statistical power through imputation, the power available to determine whether a particular component of the metabolic syndrome was driving the relationship of interest remained somewhat limited. In total, there were only 121 CHD deaths with particularly few events occurring in some of the exposure categories created on the basis of gender, diabetes status, and each NCEP-MetS component part in turn.
One possible explanation for increased cardiovascular risk in women with both NCEP-MetS and diabetes could be a longer duration of diabetes, or more severe diabetes. However, in our study among individuals with diabetes, age at diabetes onset, and duration of diabetes were similar in men and women regardless of whether or not they also had NCEP-MetS. Moreover, among individuals with diabetes and no history of CVD, the difference in HRs for NCEPMetS in relation to CHD mortality between men and women was only slightly attenuated by adjustment for duration of diabetes or 2-hour glucose levels. A second possible explanation for the increased cardiovascular risk in women with both NCEP-MetS and diabetes could be more aggressive treatment of the component parts of the metabolic syndrome in men than in women because of greater perceived risk among men. Moreover, differential treatment of the component parts of the metabolic syndrome in men and women is likely to be exacerbated by the major developments in treatment which occurred during the study. Unfortunately we do not have information available on treatment throughout the follow-up period to test this hypothesis. Finally, it is important to bear in mind that the greater impact of diabetes and the metabolic syndrome on cardiovascular risk in women is largely a result of lower baseline risk in women than in men in individuals without NCEP-MetS or diabetes.
Obesity, specifically increased central adiposity, is an underlying component of the metabolic syndrome that differentially affects men and women. In general, men tend to have a lower percentage of total fat, but higher amounts of central or visceral adiposity (22) (23) (24) . The Strong Heart Study examined sex-specific differences between diabetic and nondiabetic individuals and similar to our findings reported that differences in waist circumference between diabetic and nondiabetic individuals were greater in women than in men (25) . Adverse lipoprotein changes between diabetic and nondiabetic individuals differentially affect women and men, are associated with obesity, and represent two components of the metabolic syndrome (18, (25) (26) (27) (28) (29) (30) (31) (32) . In (18, 33) . Adverse lipoprotein changes reported in other studies include greater decreases in HDL cholesterol, apolipoprotein A-I and LDL size and greater increases in LDL cholesterol and apoliprotein B in diabetic women than in diabetic men (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) . In summary, when diabetes occurred with the metabolic syndrome, CHD mortality rates were similar in men and women; whereas in individuals with neither disorder, CHD mortality rates were significantly lower in women than in men. Thus, gender was a strong modifier of the joint effect of diabetes and NCEP-MetS on CHD mortality, suggesting that the metabolic syndrome when coupled with diabetes may affect men and women differentially relative to CHD mortality.
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